Recursion PharmaceuticalsRXRX
RXRX
About: Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Employees: 800
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
163% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 32
90% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 60
67% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 10 (+4) [Q4]
20% more capital invested
Capital invested by funds: $1.72B [Q3] → $2.06B (+$341M) [Q4]
18% more funds holding
Funds holding: 264 [Q3] → 312 (+48) [Q4]
1% less call options, than puts
Call options by funds: $30.7M | Put options by funds: $30.9M
13.52% less ownership
Funds ownership: 92.93% [Q3] → 79.41% (-13.52%) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
7%
upside
Avg. target
$8.33
49%
upside
High target
$11
97%
upside
3 analyst ratings
1 positive
33%
2 neutral
67%
0 negative
0%
Morgan Stanley Vikram Purohit 40% 1-year accuracy 2 / 5 met price target | 43%upside $8 | Equal-Weight Maintained | 10 Apr 2025 |
Needham Gil Blum 18% 1-year accuracy 29 / 158 met price target | 97%upside $11 | Buy Reiterated | 8 Apr 2025 |
Leerink Partners Mani Foroohar 36% 1-year accuracy 5 / 14 met price target | 7%upside $6 | Market Perform Maintained | 28 Feb 2025 |
Financial journalist opinion
Based on 13 articles about RXRX published over the past 30 days
Positive
Zacks Investment Research
2 days ago
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $5.84, denoting a +1.83% change from the preceding trading day.
Neutral
GlobeNewsWire
2 days ago
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th
Company to host public (L)earnings call on May 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT Company to host public (L)earnings call on May 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT
Positive
The Motley Fool
1 week ago
3 Monster Stocks to Hold for the Next 10 Years
Got a little money and a lot of time? Say, 10 years or more?
Neutral
GlobeNewsWire
1 week ago
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data during the 2025 Digestive Disease Week (DDW) meeting from its ongoing Phase 1b/2 clinical trial, TUPELO, which is evaluating the safety and preliminary activity of REC-4881 for the treatment of familial adenomatous polyposis (FAP). The data will be presented as a late-breaking oral presentation during the Research Forum session on Hereditary GI cancer syndromes on Sunday, May 4, 2025 in San Diego.
Positive
Finbold
1 week ago
Investment strategist picks 3 ‘new age' healthcare stocks to buy
Investment strategist Shay Boloor has highlighted three companies driving the “new age” of healthcare, making them must-watch opportunities for investors.
Neutral
The Motley Fool
1 week ago
This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy?
Artificial intelligence (AI) is taking over the world. Individuals and corporations are implementing the technology in their day-to-day lives and operations; governmental institutions are doing the same.
Neutral
PRNewsWire
2 weeks ago
HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data
PHILADELPHIA , April 16, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, has licensed its real-world data to enhance clinical trial design and analytics. Through this agreement, Recursion will integrate HealthVerity de-identified data for over 340M covered lives within the US into its advanced data science and machine learning platforms, the Recursion OS, allowing for deeper insights into patient populations, enhanced trial design and feasibility assessments, as well as clinical operations workflows.
Positive
Zacks Investment Research
2 weeks ago
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?
Recursion Pharmaceuticals (RXRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Positive
The Motley Fool
2 weeks ago
Why Recursion Pharmaceuticals Stock Is Skyrocketing Today
Shares of Recursion Pharmaceuticals (RXRX 17.52%) were skyrocketing around 20% higher as of 11 a.m. ET on Friday.
Neutral
Zacks Investment Research
3 weeks ago
RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study
Recursion Pharmaceuticals doses the first patient in a phase I study of its investigational candidate, REC-3565, for treating B-cell lymphomas.
Charts implemented using Lightweight Charts™